These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26481299)

  • 1. Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy.
    Chiricozzi A; Cannizzaro MV; Salandri GA; Marinari B; Pitocco R; Dattola A; Regine F; Saraceno R; Bianchi L; Chimenti S; Costanzo A
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e128-e129. PubMed ID: 26481299
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure.
    Kusakari Y; Yamasaki K; Takahashi T; Tsuchiyama K; Shimada-Omori R; Nasu-Tamabuchi M; Aiba S
    J Dermatol; 2015 Jul; 42(7):727-30. PubMed ID: 25916786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.
    Balato A; Schiattarella M; Di Caprio R; Lembo S; Mattii M; Balato N; Ayala F
    J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1016-24. PubMed ID: 24033358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):92-5. PubMed ID: 25650695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for severe psoriasis in Chilean paediatric patients.
    Armijo Fernandez D; Valenzuela F; Saint-Pierre Contreras G; Cortés González A
    An Bras Dermatol; 2020; 95(1):105-106. PubMed ID: 31959513
    [No Abstract]   [Full Text] [Related]  

  • 8. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.
    Adenubiova E; Arenberger P; Gkalpakioti P; Arenbergerova M; Jircikova J; Dolezal T; Gkalpakiotis S
    J Dermatolog Treat; 2018 Sep; 29(6):579-582. PubMed ID: 29307245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy.
    Buffiere-Morgado A; Couderc E; Delwail A; Favot L; Jegou JF; Solau E; Guillet G; Lecron JC; Morel F
    Eur J Dermatol; 2017 Dec; 27(6):579-589. PubMed ID: 29171393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW; Villanueva Quintero DG; Echeverría CM; Gu Y; Karunaratne M; Reyes Servín O
    Am J Clin Dermatol; 2016 Dec; 17(6):691-699. PubMed ID: 27815915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed ANA dynamics under adalimumab therapy show no significant correlation to PASI response and MTX cotreatment: a retrospective study of 98 psoriasis patients.
    Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e128-e129. PubMed ID: 30394590
    [No Abstract]   [Full Text] [Related]  

  • 15. Resolution of psoriatic lesions on the gingiva and hard palate following administration of adalimumab for cutaneous psoriasis.
    Brooks JK; Kleinman JW; Modly CE; Basile JR
    Cutis; 2017 Feb; 99(2):139-142. PubMed ID: 28319621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-α treatment.
    Balato A; Lembo S; Ayala F; Balato N; Caiazzo G; Raimondo A; Di Caprio R; Monfrecola G
    Exp Dermatol; 2017 Apr; 26(4):325-327. PubMed ID: 27943462
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
    Bongiorno MR; Pistone G; Doukaki S; Aricò M
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab.
    Gkalpakiotis S; Arenberger P; Gkalpakioti P; Hugo J; Sticova E; Tesinsky P; Arenbergerová M
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2063-4. PubMed ID: 24981161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.